Article Text
Statistics from Altmetric.com
We congratulate Georgopoulos et al,1 for their excellent paper on intraocular inflammation with use of intravitreal bevacizumab (Avastin). Along with the efficacy, safety and tolerability is a key issue with the use of anti-VEGF agents,2 3 as ranibizumab (Lucentis) is now the standard of care for neovascular age-related macular degeneration according to NICE UK recommendations.4 5 However, the spectrum of off-label therapeutic indications for anti-VEGF agents …
Footnotes
Linked articles 166918
Competing interests None.
Provenance and peer review Not commissioned; not externally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Linked Articles
- PostScript